Early and Intensive Therapy for Management of Hyperglycemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes

Clinical Therapeutics

Volumn 33, Issue 6, 2011, Pages 665-678

  Dailey, George ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

cell function; Cardiovascular disease; Early intervention; Glycemic control; Glycosylated hemoglobin; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; METFORMIN; SULFONYLUREA;

ARTICLE; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; EMBASE; FOLLOW UP; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INTENSIVE CARE; LONG TERM CARE; MEDICAL HISTORY; MEDLINE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; UNITED KINGDOM;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 79959439378     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.04.025     Document Type: Article

References (43)

1. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 2011, Centers for Disease Control and Prevention, US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga.
2. National diabetes statistics 2007, National Diabetes Information Clearinghouse, Updated June 2008, Accessed March 29, 2010. http://diabetes.niddk.nih.gov/dm/pubs/statistics.
3. Bate K.L., Jerums G. Preventing complications of diabetes. Med J Aust 2003, 179:498-503.
4. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:480-486. American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
5. Erhardt L.R. Rationale for multiple risk intervention: the need to move from theory to practice. Vasc Health Risk Manag 2007, 3:985-997.
6. Standards of medical care in diabetes-2010. Diabetes Care 2010, 33(Suppl 1):S11-S61. American Diabetes Association.
7. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
8. Rustenbeck I., Krautheim A., Jörns A., Steinfelder H.J. Beta-cell toxicity of ATP-sensitive K+ channel-blocking insulin secretagogues. Biochem Pharmacol 2004, 67:1733-1741.
9. DeFronzo R.A. Banting lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
10. Wajchenberg B.L. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007, 28:187-218.
11. Klonoff D.C., Buse J.B., Nielsen L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
12. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
13. Saydah S.H., Fradkin J., Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335-342.
14. Ong K.L., Cheung B.M., Wong L.Y., et al. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2008, 18:222-229.
15. Cheung B.M.Y., Ong K.L., Cherny S.S., et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009, 122:443-453.
16. Iqbal N. The burden of type 2 diabetes: strategies to prevent or delay onset. Vasc Health Risk Manag 2007, 3:511-520.
17. Del Prato S., Wishner W.J., Gromada J., Schluchter B.J. Beta-cell mass plasticity in type 2 diabetes. Diabetes Obes Metab 2004, 6:319-331.
18. Standl E. The importance of beta-cell management in type 2 diabetes. Int J Clin Pract Suppl 2007, 153:10-19.
19. Skyler J.S., Bergenstal R., Bonow R., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Diabetes Care 2009, 32:187-192.
20. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group.
21. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release and Controlled Evaluation (ADVANCE) Collaborative Group.
22. Duckworth W.C., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139. VADT Investigators.
23. Currie C.J., Peters J.R., Tynan A., et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010, 375:481-489.
24. Gæde P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
25. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
26. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
27. Hypoglycemia associated with increased risk of MI among US veterans with diabetes October 5, 2009, [news release], Heartwire, Vienna, Austria, Updated, Accessed March 29, 2010. http://www.theheart.org/article/1010567.do.
28. Reaven P.D., Moritz T.E., Schwenke D.C., et al. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes 2009, 58:2642-2648.
29. Tabak A.G., Jokela M., Akbaraly T., et al. Trajectories of glycemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009, 373:2215-2221.
30. Matthews D.R., Cull C.A., Stratton I.M., et al. UKPDS 26: Sulfonylurea failure in non-insulin-dependent diabetic patients over six years. Diabetic Med 1998, 15:297-303.
31. Turner R.C., Cull C.A., Frighi V., et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. JAMA 1999, 281:2005-2012. UKPDS 49 Study Group.
32. Xiang A.H., Peters R.K., Kjos S.L., et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006, 55:517-522.
33. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, glyburide, or metformin monotherapy. N Engl J Med 2006, 355:2427-2443.
34. ACTos NOW for the Prevention of Diabetes (ACTNOW)Study. Pioglitazone prevents conversion to diabetes among insulin-resistant patients. Presented at the 68th Scientific Sessions of the American Diabetes Association, San Francisco, CA, June 11, 2008. Updated June 11, 2008. Accessed March 29, 2010. http://www.docguide.com/news/content.nsf/news/852571020057CCF68525746004F379A.
35. Kendall D.M. Thiazolidinediones: the case for early use. Diabetes Care 2006, 29:154-156.
36. Buse J.B., Henry R.R., Han J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
37. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
38. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
39. Bunck M.C., Diamant M., Cornér A., et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009, 32:762-768.
40. Madsbad S. Liraglutide Effect and Action in Diabetes (LEAD) trial. Expert Rev Endocrinol Metab 2009, 4:119-129.
41. Nauck M.A., Ratner R.E., Kapitza C., et al. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009, 32:1237-1243.
42. Rosenstock J., Reusch J., Bush M., et al. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009, 32:1880-1886. Albiglutide Study Group.
43. Tourrel C., Bailbe D., Lacorne M., et al. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002, 51:1443-1452.